ANIX (Anixa Biosciences) Change In Working Capital: $-0.27 Mil (TTM As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIX Anixa Biosciences Inc ANIX
32 GF Score
Price $3.07
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Change In Working Capital?

Anixa Biosciences ANIX +0.91% 32 Change In Working Capital is $-0.27 Mil as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Anixa Biosciences's change in working capital for the quarter that ended in Apr. 2026 was $0.10 Mil.

Anixa Biosciences's change in working capital for the fiscal year that ended in Oct. 2025 was $0.15 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Anixa Biosciences Change In Working Capital Related Terms

Anixa Biosciences Change In Working Capital Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Change In Working Capital Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Change In Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.49 -1.06 0.53 0.15

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 -0.08 0.60 -0.88 0.10
ANIX
32GF Score
Anixa Biosciences Inc ANIX
Change In Working Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.27 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Working Capital of $-0.27 Mil mean?
Anixa Biosciences (ANIX) has a Change In Working Capital of $-0.27 Mil as of Apr. 2026. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Anixa Biosciences.
Is Anixa Biosciences' Change In Working Capital too high?
Anixa Biosciences' current Change In Working Capital is $-0.27 Mil. Overall, Anixa Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Change In Working Capital compare to GNLX and PMN?
Anixa Biosciences' Change In Working Capital of $-0.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Working Capital for a Biotechnology company?
A good Change In Working Capital depends on the Biotechnology industry context. However, Change In Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Working Capital mean?
A high Change In Working Capital can signal that a stock is expensive relative to its fundamentals. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Anixa Biosciences. Anixa Biosciences's current Change In Working Capital is $-0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Change In Working Capital of $-0.27 Mil. The current Change In Working Capital is $-0.27 Mil. Anixa Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Working Capital calculated?
Change In Working Capital is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Change In Working Capital is $-0.27 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
32GF Score

Get the complete analysis for ANIX

Change In Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.07
Price